- Home
- WHWK vs ONCY Comparison
WHWK vs ONCY Comparison
Compare WHWK & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | ONCY |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 94.0M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | WHWK | ONCY |
|---|---|---|
| Price | $2.72 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $7.00 | $6.00 |
| AVG Volume (30 Days) | 108.0K | ★ 1.3M |
| Earning Date | 02-24-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.33 |
| 52 Week High | $3.77 | $1.51 |
Technical Indicators
Market Signals| Indicator | WHWK | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 45.70 |
| Support Level | $2.60 | $0.98 |
| Resistance Level | $2.83 | $1.30 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 41.47 | 18.08 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.